Matthias Schmidt MD, Presenter: Nothing to Disclose

1) To understand the molecular basis for imaging and therapy of neuroendocrine tumors with metaiodobenzylguanidine (MIBG). 2) To be able to define indications for imaging of neuroendocrine tumors (i.e. pheochromocytoma, paraganglioma and neuroblastoma) with MIBG and when to consider other radiopharmaceuticals. 3) Learn to read typical and difficult cases imaged with metaiodobenzylguanidine. 4) To understand the historical development of I-131-mIBG therapy and its current use in neuroendocrine tumors and high-risk neuroblastoma. 5) To address important aspects how to deliver I-131-mIBG therapy with different aspects concerning adult versus pediatric patients.

Schmidt, M, Imaging and Therapy of Neuroendocrine Tumors with MIBG.  Radiological Society of North America 2014 Scientific Assembly and Annual Meeting, - ,Chicago IL. http://archive.rsna.org/2014/14019822.html